Adams EH, Hunter TS, Williams T. New options in the treatment of arthritis. J Manage Care Pharm 1999 Sep 31; 5: 443–8
Carr DB, Goudas LC. Acute Pain. Lancet 1999 Jun 12; 353: 2051–8PubMedCrossRef
Botting JH. Nonsteroidal antiinflammatory agents. Drugs Today 1999 Apr; 35: 225–35PubMed
Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61(8): 1133–41; discussion 1142-3PubMedCrossRef
Fiechtner JJ, Sikes D, Recker D. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee [abstract no. OP0048]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic
Daniels SE, Talwalker S, Hubbard RC, et al. Pre-operative valdecoxib, a COX-2 specific inhibitor, provides effective and long lasting pain relief following oral surgery [abstract no. A-810]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.
Dejardins PJ, Talwalker S, Hubbard RC, et al. Pre-operative administration of valdecoxib, a potent COX-2 specific inhibitor, provides effective post-operative analgesia [abstract no. A-811]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana
Camu F, Beecher T, Recker DP, et al. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002 Jan 28; 9(1): 43–51PubMedCrossRef
Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-pheny-lisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX- 2. J Med Chem 2000 Mar 9; 43(5): 775–7PubMedCrossRef
Leese PT, Recker D, Kuss ME. The novel COX-2 specific inhibitor, valdecoxib, does not affect platelet function in healthy adults [abstract no. 043]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic.
Leese PT, Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly [abstract no. 042]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic.
Pharmacia Corporation. Bextra, valdecoxib tablets. Product information [online]. Available from URL: http://www.pnu.com
[Accessed 2002 Aug 12]
Kharasch E, Ibrahim A, Karim A, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the pharmacokinetics and clinical effects of fentanyl and alfentanil [abstract no. A-450]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.
Noroian G, Clive D. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Drug Saf 2002; 25(3): 165–72PubMedCrossRef
Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002 Jun;51(6):530–7PubMed
Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002 Apr; 10(4): 290–6PubMedCrossRef
Bensen W, Weaver A, Espinoza L, et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis [abstractno. 1896]. Arthritis Rheum 2001; 44 (9 Suppl.): 369
Daniels SE, Desjardins PJ, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/ acetaminophen after oral surgery. J Am Dent Assoc 2002 May; 133(5): 611–21
Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002 Mar; 9(2): 89–97PubMedCrossRef
Daniels DE, Torris S, Snabes MC. Efficacy of valdecoxib versus naproxen sodium in primary dysmenorrhea. Obstet Gynecol 2002; 99 Suppl.: 30S–1S
Camu F, Beecher T, Talwalker S, et al. The COX-2 specific inhibitor valdecoxib is opioid-sparing and provides effective analgesia in primary hip arthroplasty patients [abstract no. A-809]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.
Goldstein JL, Fakouhi KM, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: a multicenter trial [abstract no. 3032]. Gastroenterology 2001 Apr; 120 Suppl. 1: 597
Goldstein JL, Stenson W, Agrawal N, et al. Valdecoxib is associated with a significantly lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID. [abstract no. T1503] Gastroenterology2002 Apr; 122 Suppl. 1: A469
Goldstein JL, Kent J, Shu V, et al. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease [abstract no. M1731]. Gastroenterology 2002 Apr; 122 Suppl. 1: A344